Which patent matters for “semaglutide’s patent expiry” (and why an “exact date” is hard to name)
“Semaglutide” has multiple patents and multiple regulatory exclusivities tied to different drugs, doses, and markets (for example, the injectable product(s) vs. oral formulations), so there is no single universal “exact date” that applies to all semaglutide products. Patent expiry depends on the specific patent family and the country where the product is marketed.
The exact expiry date can only be given by identifying:
the relevant patent number (or patent family) and country,
the product/indication and dosage form it covers,
and whether any patent term adjustments, extensions, or regulatory exclusivities apply in that jurisdiction.
What I can say with the info provided here
No patent number, jurisdiction, or product brand (for example, Ozempic/Wegovy/Rybelsus) was provided, and no source documents were included. Without that, I can’t determine an exact calendar expiry date for semaglutide.
What to send so I can give you the exact expiry date
Reply with one of the following, and I’ll produce the exact expiry date:
1) The jurisdiction (e.g., US, UK, EU, Canada, Japan) and the brand/product you mean (injectable or oral), or
2) The patent number(s) you’re referring to, or
3) A link/name of the patent or patent list you found.
Common pitfall: “first generic entry date” vs “patent expiry date”
Even after the last relevant patent expires, launch timing can still be delayed by:
other still-active patents (process, formulation, specific dose/combination),
regulatory exclusivity rules,
and ongoing litigation or settlements.
So “patent expiry date” and “generic/biosimilar availability” are often different.
---
If you tell me the country and which semaglutide product you mean (Ozempic, Wegovy, or Rybelsus), I can pin down the exact expiry date for the specific patent(s) involved.